Radioactive ray of hope: first test of new drug for deadly eye cancer
NCT ID NCT05496686
Summary
This is the first-ever study in people of an experimental radioactive drug called 225Ac-MTI-201. It aims to find the safest dose for patients with metastatic uveal melanoma, a rare and aggressive eye cancer that has spread after other treatments failed. The study will also track how the drug moves through the body and look for early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.